arsenic has been researched along with Leukemia, Myelogenous, Aggressive Phase in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Firkin, F | 1 |
| Huang, Q | 1 |
2 other study(ies) available for arsenic and Leukemia, Myelogenous, Aggressive Phase
| Article | Year |
|---|---|
Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study.
Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Australia; Female; Growth Inhibitors; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2012 |
Chronic myelogenous leukemia in accelerated phase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic | 2005 |